Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.18632/oncotarget.3597 http://scihub22266oqcxt.onion/10.18632/oncotarget.3597 C4484458!4484458 !25888637     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 265.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 265.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Warning: imagejpeg(C:\Inetpub\vhosts\kidney.de\httpdocs\phplern\25888637 .jpg): Failed to open stream: No such file or directory in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 117       Oncotarget 2015 ; 6 (13 ): 11310-26 Nephropedia Template TP {{tp|p=25888637 |t=2015. Targeting myeloid cells in the tumor microenvironment enhances vaccine efficacy in murine epithelial ovarian cancer |pdf=|usr=}}{{25888637 }} gab.com Text Targeting myeloid cells in the tumor microenvironment enhances vaccine efficacy in murine epithelial ovarian cancer JO: Oncotarget http://www.kidney.de/pget.php?&tw=1&pmid=25888637 #FOAvip Epithelial ovarian cancer (EOC) is typically diagnosed at advanced stages, and is associated with a high relapse rate. Patients in remission are ideal candidates for immunotherapy aimed at cure or prolonging disease-free periods. However, immunosuppressive pathways in the tumor microenvironment are obstacles to durable anti-tumor immunity. In a metastatic syngeneic mouse model of EOC, immunosuppressive macrophages and myeloid-derived suppressor cells (MDSCs) accumulate in the local tumor environment. In addition, resident peritoneal macrophages from non-tumor-bearing mice were highly immunosuppressive, abrogating stimulated T cell proliferation in a cell contact-dependent manner. Immunization with microparticles containing TLR9 and NOD-2 ligands (MIS416) significantly prolonged survival in tumor-bearing mice. The strategy of MIS416 immunization followed by anti-CD11b administration further delayed tumor progression, thereby establishing the proof of principle that myeloid depletion can enhance vaccine efficacy. In patients with advanced EOC, ascites analysis showed substantial heterogeneity in the relative proportions of myeloid subsets and their immunosuppressive properties. Together, these findings point to immunosuppressive myeloid cells in the EOC microenvironment as targets to enhance vaccination. Further studies of myeloid cell accumulation and functional phenotypes in the EOC microenvironment may identify patients who are likely to benefit from vaccination combined with approaches that deplete tumor-associated myeloid cells. Twit Text FOAVip Targeting myeloid cells in the tumor microenvironment enhances vaccine efficacy in murine epithelial ovarian cancer ????Oncotarget http://www.kidney.de/pget.php?&tw=1&pmid=25888637 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=25888637 #FOAvip English Wikipedia <ref>{{Cite pmid|25888637 }}</ref> Targeting myeloid cells in the tumor microenvironment enhances vaccine efficacy in murine epithelial ovarian cancer #MMPMID25888637 Khan AN ; Kolomeyevskaya N ; Singel KL ; Grimm MJ ; Moysich KB ; Daudi S ; Grzankowski KS ; Lele S ; Ylagan L ; Webster GA ; Abrams SI ; Odunsi K ; Segal BH Oncotarget 2015[May]; 6 (13 ): 11310-26 PMID25888637 show ga Epithelial ovarian cancer (EOC) is typically diagnosed at advanced stages, and is associated with a high relapse rate. Patients in remission are ideal candidates for immunotherapy aimed at cure or prolonging disease-free periods. However, immunosuppressive pathways in the tumor microenvironment are obstacles to durable anti-tumor immunity. In a metastatic syngeneic mouse model of EOC, immunosuppressive macrophages and myeloid-derived suppressor cells (MDSCs) accumulate in the local tumor environment. In addition, resident peritoneal macrophages from non-tumor-bearing mice were highly immunosuppressive, abrogating stimulated T cell proliferation in a cell contact-dependent manner. Immunization with microparticles containing TLR9 and NOD-2 ligands (MIS416) significantly prolonged survival in tumor-bearing mice. The strategy of MIS416 immunization followed by anti-CD11b administration further delayed tumor progression, thereby establishing the proof of principle that myeloid depletion can enhance vaccine efficacy. In patients with advanced EOC, ascites analysis showed substantial heterogeneity in the relative proportions of myeloid subsets and their immunosuppressive properties. Together, these findings point to immunosuppressive myeloid cells in the EOC microenvironment as targets to enhance vaccination. Further studies of myeloid cell accumulation and functional phenotypes in the EOC microenvironment may identify patients who are likely to benefit from vaccination combined with approaches that deplete tumor-associated myeloid cells. |*Tumor Escape [MESH] |*Tumor Microenvironment [MESH] |*Vaccination [MESH] |Adoptive Transfer [MESH] |Animals [MESH] |Antibodies, Monoclonal/*administration & dosage/immunology [MESH] |Ascites/immunology [MESH] |CD11b Antigen/immunology [MESH] |Cancer Vaccines/*administration & dosage/immunology [MESH] |Carcinoma, Ovarian Epithelial [MESH] |Cell Line, Tumor [MESH] |Cell Proliferation [MESH] |Coculture Techniques [MESH] |Disease Progression [MESH] |Female [MESH] |Humans [MESH] |Ligands [MESH] |Lymphocyte Activation [MESH] |Lymphocytes, Tumor-Infiltrating/immunology [MESH] |Macrophages/immunology [MESH] |Mice, Inbred C57BL [MESH] |Mice, Transgenic [MESH] |Myeloid Cells/*immunology [MESH] |Neoplasms, Glandular and Epithelial/genetics/immunology/pathology/*therapy [MESH] |Nod2 Signaling Adaptor Protein/immunology [MESH] |Ovalbumin/administration & dosage/immunology [MESH] |Ovarian Neoplasms/genetics/immunology/pathology/*therapy [MESH] |T-Lymphocytes/immunology [MESH] |Time Factors [MESH]Targeting myeloid cells in the tumor microenvironment enhances vaccine(epmc).pdf DeepDyve Pubget Overpricing